Phase I clinical trial of tamoxifen and interferon alpha in the treatment of solid tumors

Journal of Applied Research

Volumn 4, Issue 3, 2004, Pages 464-469

  Jazieh, Abdul Rahman ^a   Kyasa, Mohammed Jameel ^b   Hutchins, Laura ^b  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Cancer; Interferon alpha; Tamoxifen

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; TAMOXIFEN;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG RECOMMENDED DOSE; FEMALE; FIXED DRUG DOSE; HUMAN; KIDNEY CANCER; LEUKOPENIA; LIVER TOXICITY; MALE; NEUROTOXICITY; PHASE 1 CLINICAL TRIAL; SOFT TISSUE SARCOMA; SOLID TUMOR; THROMBOCYTOPENIA; THYROTOXICOSIS;

EID: 4644246521     PISSN: 1537064X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Folkman J. Clinical applications of research on angiogenesis. N Engl J Med. 1995;333:1757-1763.
2. Sidky YA, Borden EC. Inhibition of angiogenesis by interferon: effects on tumor and lymphocyte inducted vascular responses. Cancer Res. 1987;47:5155-5161.
3. Iwagak H, Hizuta A, Yoshino T, et al. Complete regression of advanced liposarcomas of the anterior chest wall with interferon alpha and tumor necrosis factors. Anticancer Res. 1993;13:13-15.
4. Rubinger M, Plenderleith IH, Lertzman M, et al. Metastatic extraskeletal myxoid chondrosarcomas. Successful therapy with Interferon alpha 2b. Chest. 1995;108:281-282.
5. Singh RK, Gutman, M, Bucana D, et al. Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas. Proceeding of the National Academy of Sciences of the United States of America. 1995;92:4562-4567.
6. Gagliardi A, Callins DC. Inhibition of angiogenesis by antiestrogen. Cancer Res. 1993;53:533-551.
7. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med. 1991;324:1-8.
8. Friedman ZY. Recent advances in understanding the molecular mechanism of tamoxifen action. Cancer Invest. 1998;16:391-396.
9. O'Brien CA, Liskamp RM, Solomon DH, et al. Inhibition of protein kinase C by tamoxifen. Cancer Res. 1985;45:2462-2465.
10. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med. 1991;324:1-8.
11. Friedman ZY. Recent advances in understanding the molecular mechanism of tamoxifen action. Cancer Invest. 1998;16:391-396.
12. Porzsot F, Otto AM, Trauschel B, et al. Rationale for combining tamoxifen and interferon in the treatment of advanced breast cancer. J Cancer Res Clin Oncol. 1989;115:465-469.
13. Lindner DJ, Borden EC. Synergistic antitumor effects of a combination of interferon and tamoxifen on estrogen receptor-positive and receptor-negative human tumor cell lines in vivo and in vitro. J Interfer Cytokine Res. 1997;17:681-693.
14. Folkman J. Clinical applications of research on angiogenesis. N Engl J Med. 1995;333:1757-1763.
15. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med. 1991;324:1-8.
16. Takebayashi, Aklyama S, Yamada K, et al. Angiogenesis as an unfavorable prognostic factor in human colorectal carcinoma. Cancer. 1996;78:226-231.
17. Fontanini G, Lucchi M, Vignati S, et al. Angiogenesis as a prognostic indicator of survival in non-small cell lung carcinoma: a prospective study. J Natl Cancer Inst. 1997;18:89:881-886.
18. Weidner N, Carroll PR, Flax J, et al. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol. 1993;143:401-409.
19. Hollingsworth HC, Kohn EC, Steinberg SM, et al. Tumor angiogenesis in advanced stage ovarian carcinoma. Am J Pathol. 1995;147:9-19.
20. Blackwell KL, Haroon ZA, Shan S, et al. Tamoxifen inhibits angiogenesis in estrogen receptor negative animal models. Clin Canc Res. 2000;6:4359-4364.
21. Gagliardi A. Inhibition of angiogenesis by antiestrogens. Cancer Res. 1993;53:533.
22. Zeev YF. Recent advances in understanding the molecular mechanisms of tamoxifen action. Cancer Invest. 1998;16:391-396.
23. Lindner DJ, Kolla V, Kalvakolanu DV, Borden EC. Tamoxifen enhances interferon regulated gene expression in breast cancer cells. Mol Cell Biochem. 1997;167:169-177.
24. Chawla-Sarkar M, Lindner DJ, Liu YF, et al. Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Aptosis. 2003;8:237-249.
25. Porzsot F, Otto AM,Trauschel B, et al. Rationale for combining tamoxifen and interferon in the treatment of advanced breast cancer. J Cancer Res Clin Oncol. 1989;115:465-469.
26. Josui K, Kubota T, Kitajima M. Recombinant human interferon-alpha 2 increases hormone receptor level of a human breast carcinoma xenograft in nude mice and enhances the anti-proliferative activity of tamoxifen. Jpn J Cancer Res. 1992;83:1347-1353.
27. van den Berg HW, Leahey WJ, Lynch M, Clarke R, Nelson J. Recombinant human Interferon alpha increases estrogen receptor expression in human breast cancer cells (ZR-75-1) and sensitizes them to the anti-proliferative effect of tamoxifen. Br J Cancer. 1987;55:255-257.
28. Sica G, Iacopina F, Delia Cung GR, Marchetti P. Recombinant interferon-alpha 2b affects proliferation, steroid receptors and sensitivity to tamoxifen of cultured breast cancer cells (CG-5). Anticancer Drugs. 1992;3:147-153.
29. Seymour L, Bezwoda WR. Interferon plus tamoxifen treatment for advanced breast cancer in vivo biologic effects of two growth modulators. Br J Cancer. 1993;68:352-356.
30. Lindner DJ. Interferons as antiangiogenic agents. Curr Oncol Rep. 2002;4:510-514.